StockNews.com Initiates Coverage on Minerva Neurosciences (NASDAQ:NERV)

StockNews.com initiated coverage on shares of Minerva Neurosciences (NASDAQ:NERV) in a report issued on Friday. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright dropped their target price on shares of Minerva Neurosciences from $7.00 to $5.00 and set a “neutral” rating for the company in a report on Wednesday, August 7th.

Minerva Neurosciences Price Performance

Minerva Neurosciences stock opened at $2.44 on Friday. The firm has a market cap of $17.06 million, a PE ratio of -0.55 and a beta of 0.14. The stock’s fifty day moving average price is $2.68 and its two-hundred day moving average price is $2.80. Minerva Neurosciences has a one year low of $2.26 and a one year high of $13.49.

Minerva Neurosciences (NASDAQ:NERV) last announced its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported ($1.09) EPS for the quarter, missing the consensus estimate of ($0.97) by ($0.12). Sell-side analysts expect that Minerva Neurosciences will post -2.26 earnings per share for the current fiscal year.

Minerva Neurosciences Company Profile

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.